Inhibrx Biosciences, Inc. Earnings

The next earnings date for Inhibrx Biosciences, Inc. is August 11, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Inhibrx Biosciences, Inc. Earnings

Report DateEstimated Earnings Per Share
08/11/2026$-1.96

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Inhibrx Biosciences, Inc. Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
05/14/2026After Market$-2.15-17.96%
03/19/2026After Market$-2.110.40%
11/14/2025Before Market$-2.28-30.11%
08/13/2025After Market$-1.8534.31%
05/14/2025After Market$-2.803.29%
03/17/2025After Market$-3.09-4.97%
11/14/2024After Market$-2.8417.60%
08/13/2024After Market$125.483,517.21%
05/09/2024After Market$-1.44-35.75%
02/28/2024Before Market$-1.73-63.61%
11/09/2023After Market$-1.10-6.78%
08/07/2023After Market$-1.08-2.50%
05/08/2023After Market$-1.12-30.10%
03/06/2023After Market$-0.95-18.19%
11/07/2022After Market$-0.906.23%
08/08/2022After Market$-0.97-22.15%
05/09/2022After Market$-0.80-30.87%
02/28/2022After Market$-0.555.79%
11/09/2021After Market$-0.546.85%
08/09/2021After Market$-0.552.93%
05/13/2021After Market$-0.5115.04%
03/12/2021Before Market$-0.4714.98%
11/13/2020After Market$-0.77-25.06%

More About Inhibrx Biosciences, Inc.

Country
USA
Full Time Employees
109

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Inhibrx Biosciences, Inc. Earnings” Can Refer to the Inhibrx Biosciences, Inc. Earnings Date

Some people say “Inhibrx Biosciences, Inc. earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Inhibrx Biosciences, Inc. position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Inhibrx Biosciences, Inc. Stock on the Earnings Date

If you own Inhibrx Biosciences, Inc. stock (INBX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Inhibrx Biosciences, Inc. might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Inhibrx Biosciences, Inc. shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Inhibrx Biosciences, Inc. Earnings

You can contact us any time if you would like to ask questions about Inhibrx Biosciences, Inc. earnings or anything else related to the stock market.